This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Voora, D. Articles by Ginsburg, G. S. Search for Related Content PubMed PubMed Citation Articles by Voora, D. Articles by Ginsburg, G. S. Related Collections Related Articles

The SLCO1B1*5 Genetic Variant Is Associated With Statin-Induced Side Effects

Deepak Voora, MD^_*,, Svati H. Shah, MD, MHS^_*,,, Ivan Spasojevic, PhD, Shazia Ali, PharmD, Carol R. Reed, MD^¶, Benjamin A. Salisbury, PhD^¶ and Geoffrey S. Ginsburg, MD, PhD^_*,,,_*

^_* Division of Cardiovascular Medicine, Duke University Medical Center, Durham, North Carolina
Center for Human Genetics, Duke University Medical Center, Durham, North Carolina
Department of Medicine, Duke University Medical Center, Durham, North Carolina
Institute for Genome Sciences & Policy, Duke University Medical Center, Durham, North Carolina
^¶ PGxHealth, LLC, New Haven, Connecticut

View larger version (30K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Statin Stratified Analyses of Adverse Events Percentage and number of those with the CAE outcome in the STRENGTH study stratified by SLCO1B1*5 genotype (top) and sex (bottom) for each assigned statin type is displayed. Carriers of SLCO1B1*5 appear to have no excess risk of CAE when assigned to pravastatin, whereas female patients appear to have an increased risk with all 3 statins. CAE = composite adverse event; STRENGTH = Statin Response Examined by Genetic Haplotype Markers.